drugset / Trial / NCT00426140

Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

NCT00426140

Phase 1 Completed 5 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies

Timeline

Start
2006-08
Primary completion
2006-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule 10 mg/m2 Intravenous

Indications